To address these challenges, RTI has developed a subcutaneous, reservoir-style implant that enables constant, zero-order PK profile through a membrane-controlled mechanism. Implant duration is currently targeted for one year of API delivery but can be reduced to accommodate shorter time frames. The biodegradable design eliminates the need for implant removal after depletion of the API and follow-up visits to a health care facility when treatment is completed. Importantly, this technology delivers user-independent API dosing and is potentially reversible and retrievable during treatment if needed. The team is currently developing the technology for HIV PrEP/treatment and contraception, and is evaluating use for other indications and medical countermeasures.